CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...
Moderna said on Monday its updated Covid-19 booster generated "significantly higher" neutralizing antibodies against the Omicron BA.4/BA.5 subvariants than its earlier shot. The bivalent booster used ...
Moderna announced Monday that a third dose of its mRNA vaccine against Covid-19 appears to provide significant protection against the omicron variant. The company said that its authorized booster can ...
Moderna said Thursday that its vaccine is 93% effective through six months after receiving the second dose. In a news release, the company added that it tested three booster shots in phase 2 of its ...
Moderna says its vaccine is 93% effective against symptomatic illness at six months (though this data collection ended before delta emerged in the U.S.). Moderna said its booster candidates also ...
A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results